Prescription medication · Serotonin-Norepinephrine Reuptake Inhibitor (SNRI)
levomilnacipran
Also sold as Fetzima. Fetzima is used to treat major depressive disorder (MDD) in adults.
Data updated 2026-05-15
- 1,858
- FDA reportsRarely reported
- 11
- InteractionsSeveral interactions
- $16.13
- Brand price (NADAC)
What the data shows
levomilnacipran (Fetzima) is a prescription Serotonin-Norepinephrine Reuptake Inhibitor (SNRI), among the least-reported drugs the FDA tracks (1,858 FDA reports), with 11 documented drug interactions.
Reporting volume reflects how widely a drug is used and studied, not how dangerous it is, a FAERS report documents a temporal association, never proof of cause.
levomilnacipran (Fetzima) is a prescription Serotonin-Norepinephrine Reuptake Inhibitor (SNRI). Fetzima is used to treat major depressive disorder (MDD) in adults.
Fetzima is a medicine used to treat major depressive disorder (MDD) in adults. It helps to improve your mood by affecting certain chemicals in the brain.
Verify with FDA → · CMS NADAC pricing →
Drug Pricing (NADAC)
Brand Price
$16.13/unit
Generic Available
No
ABBVIE
Pricing data from NADAC (CMS), effective January 2, 2024. Compare all drug costs →
What it does
Fetzima is used to treat major depressive disorder (MDD) in adults.
Common side effects
Nausea, Constipation, Increased sweating
Key warnings
Antidepressants may increase the risk of suicidal thoughts and behaviors in young adults.
The sections below are summarized in plain English from levomilnacipran's FDA-approved prescribing information. They describe what the official label says, and are not personal medical advice.
How It Works
Fetzima is a type of drug called a serotonin-norepinephrine reuptake inhibitor (SNRI). It works by increasing the levels of serotonin and norepinephrine in your brain. These chemicals can help improve your mood and reduce symptoms of depression.
Side Effects (from patient reports)
Based on 1,858 FDA adverse event reports.
Most-reported reactions
Adverse reactions in FAERS for levomilnacipran, by number of reports
- Pain
Pain
210 reports
- Vomiting
Vomiting
208 reports
- Memory Impairment
Memory Impairment
189 reports
- Paraesthesia
Paraesthesia
179 reports
- Hypoaesthesia
Hypoaesthesia
178 reports
- Abdominal Pain Upper
Abdominal Pain Upper
175 reports
- Migraine
Migraine
170 reports
- Gastrooesophageal Reflux Disease
Gastrooesophageal Reflux Disease
168 reports
- Taste Disorder
Taste Disorder
157 reports
- Epilepsy
Epilepsy
155 reports
What this shows Bars show how often each reaction was reported, not how likely it is to happen, a report records a temporal association, never proof that the drug caused it.
Reports over time
Adverse-event reports filed for levomilnacipran each year to the FDA Adverse Event Reporting System (FAERS).
Year-to-year volume tracks usage, prescribing, and scrutiny, not a change in per-patient risk. Source: FDA FAERS.
Where levomilnacipran sits
levomilnacipran has more FDA adverse-event reports than 12% of the drugs FAERS tracks. A high position reflects how widely a drug is used and watched, not how dangerous it is.
Percentile across all drugs PlainMeds tracks by FAERS report volume. The dot is levomilnacipran; the line is the median (50th percentile).
FDA Adverse Event Report Analysis
Detailed analysis of 1,858 reports from the FDA Adverse Event Reporting System (FAERS). Reports span 2013–2025.
Total Reports
1,858
Reports Mentioning Death
154
8.3% of reports — not proof of cause
Hospitalization Reports
283
Top Indication
Product Used For Unknown Indication
Gender Distribution
Age Distribution
Most Reported Adverse Reactions (FAERS)
| # | Reaction | Reports |
|---|---|---|
| 3 | PAIN | 210 |
| 4 | VOMITING | 208 |
| 5 | MEMORY IMPAIRMENT | 189 |
| 6 | PARAESTHESIA | 179 |
| 7 | HYPOAESTHESIA | 178 |
| 8 | ABDOMINAL PAIN UPPER | 175 |
| 9 | MIGRAINE | 170 |
| 10 | GASTROOESOPHAGEAL REFLUX DISEASE | 168 |
| 12 | TASTE DISORDER | 157 |
| 13 | EPILEPSY | 155 |
| 14 | BLEPHAROSPASM | 152 |
| 15 | NAUSEA | 143 |
| 16 | CONDITION AGGRAVATED | 135 |
| 17 | DEPRESSION | 114 |
| 18 | HEADACHE | 112 |
Reactions in Death Reports
Reactions in Hospitalization Reports
Source: FDA FAERS (Adverse Event Reporting System) Reports are voluntary and do not establish causation
Serious Warnings
Antidepressants may increase the risk of suicidal thoughts and behaviors in young adults. Your doctor should closely watch you for worsening depression or suicidal thoughts. Fetzima is not approved for use in children.
Known Drug Interactions
Within 14 days of stopping an MAOI intended to treat psychiatric disorders In a patient who is being treated with linezolid or intravenous methylene blue [see Dosage and Administration ( 2.5 , 2.6 ), Contraindications ( 4 ), and Warnings and Precautions ( 5.2 )] . Examples: selegiline, tranylcypromine, isocarboxazid, phenelzine, linezolid, methylene blue Other Serotonergic Drugs Clinical Impact: Concomitant use of FETZIMA with other serotonergic drugs increases the risk of serotonin syndrome.
Mechanism: Both of these medications increase the levels of a brain chemical called serotonin. If levels get too high, it can lead to a serious and potentially life-threatening reaction.
Examples: selegiline, tranylcypromine, isocarboxazid, phenelzine, linezolid, methylene blue Other Serotonergic Drugs Clinical Impact: Concomitant use of FETZIMA with other serotonergic drugs increases the risk of serotonin syndrome.
Mechanism: Both drugs increase serotonin levels in the brain, which can lead to a dangerous buildup called serotonin syndrome.
Examples: selegiline, tranylcypromine, isocarboxazid, phenelzine, linezolid, methylene blue Other Serotonergic Drugs Clinical Impact: Concomitant use of FETZIMA with other serotonergic drugs increases the risk of serotonin syndrome.
Mechanism: These drugs both raise serotonin levels, and using them at the same time can cause too much serotonin to build up in your body.
Examples: selegiline, tranylcypromine, isocarboxazid, phenelzine, linezolid, methylene blue Other Serotonergic Drugs Clinical Impact: Concomitant use of FETZIMA with other serotonergic drugs increases the risk of serotonin syndrome.
Mechanism: Taking these medications together can cause serotonin levels to become dangerously high, leading to a condition called serotonin syndrome.
Examples: other SNRIs, SSRIs, triptans, tricyclic antidepressants, opioids, lithium, buspirone, amphetamines, tryptophan, and St.
Mechanism: Both of these medicines increase the levels of a brain chemical called serotonin. Taking them together can cause serotonin levels to become dangerously high.
This is a plain-language summary of FDA-label interaction records and does not provide individual medication-combination directions.
Common Questions
What should I do if I feel worse after starting Fetzima?
Can I drink alcohol while taking Fetzima?
What if I have kidney problems?
Can I stop taking Fetzima suddenly?
Will Fetzima affect my other medications?
How long does it take for Fetzima to start working?
What if I have bipolar disorder?
Can Fetzima cause sexual side effects?
What if I need surgery?
Is there a generic version of Fetzima?
What are the common side effects of levomilnacipran?
Does levomilnacipran interact with other medications?
What drug class is levomilnacipran?
What pregnancy or breastfeeding source fields are listed for levomilnacipran?
Related Medications in Serotonin-Norepinephrine Reuptake Inhibitor (SNRI)
Other drugs grouped near levomilnacipran - same-class peers and common alternatives.
acamprosate
Campral
Acamprosate is a medicine that can help you stay away from alcohol if you are alcohol-dependent and have already stopped drinking.
Compare with levomilnacipran →
alprazolam
Xanax
Alprazolam (Xanax) is a medication that can help you with anxiety and panic disorders.
Compare with levomilnacipran →
amitriptyline
Elavil
Amitriptyline is a medicine used to treat depression.
Compare with levomilnacipran →
amphetamine/dextroamphetamine
Adderall, Adderall XR
Adderall XR is a stimulant medicine.
Compare with levomilnacipran →
aripiprazole
Abilify
Aripiprazole (Abilify) is a medicine used to treat certain mental disorders and mood problems.
Compare with levomilnacipran →
Compare beyond drug class
Nationwide peers by FAERS volume & death-report share
Two PlainMeds-derived comparison paths for levomilnacipran: nearest FDA FAERS report volume and nearest death-report share among drugs with at least 1,000 logged reports, excluding same-class neighbors listed above. Counts reflect reporting volume, not proven individual harm.
Similar FAERS report volume
Nearest drugs by total FAERS reports. This record: 1,858.
Similar death-report share
Nearest drugs by FAERS death-report share. This record: 8.29%.
- lithium Δ 0.01 pts · 24,367 reports · Mood Stabilizer 8.29%death share
- leflunomide Δ 0.01 pts · 102,095 reports · Disease-Modifying Antirheumatic Drug (DMARD) 8.28%death share
- acarbose Δ 0.01 pts · 3,736 reports · Alpha-Glucosidase Inhibitor 8.30%death share
- methimazole Δ 0.01 pts · 7,411 reports · Anti-Thyroid Agent 8.30%death share
Medication Guides
Understanding Drug Interactions
How CYP450 enzymes, inhibitors, and inducers affect your medications
Generic vs Brand Name Drugs
FDA requirements, cost savings, and when the difference matters
Narrow Therapeutic Index Drugs
FDA bioequivalence and label-record context for narrow therapeutic index medicines
Common Drug Interactions
Dangerous medication combinations and how to protect yourself
Save on levomilnacipran
Compare prices and find discounts at pharmacies near you. Free coupons can save up to 80% on prescriptions.
Disclosure: This link may earn us a commission at no extra cost to you. See our terms.
What the FDA Data Shows for levomilnacipran
The FDA label for levomilnacipran (sold under brand names such as Fetzima) classifies it as a prescription-only medication in the Serotonin-Norepinephrine Reuptake Inhibitor (SNRI) class. Fetzima is used to treat major depressive disorder (MDD) in adults. Official labeling lists 9 commonly reported side effects, including Nausea, Constipation, Increased sweating.
Post-market surveillance from the FDA Adverse Event Reporting System (FAERS) captures real-world experience. For this drug, FAERS contains 1,858 voluntary reports. The database also lists 11 documented drug interactions derived from FDA labeling, with the top-flagged interaction rated moderate severity. NADAC pricing from CMS.
Report counts do not establish causation, a FAERS entry documents a temporal association, not proof that the drug produced the outcome. Widely prescribed medications naturally accumulate more reports than niche therapies, so raw totals must be interpreted alongside total exposure. Shortage status, recall history, and patent information are separate source-record fields. This page is a public FDA/CMS registry and does not provide medical, treatment, substitution, or medication-change directions.
Data Sources
Drug labeling: FDA Drug Labels (SPL/DailyMed). Adverse events: FDA Adverse Event Reporting System (FAERS). Pricing: CMS National Average Drug Acquisition Cost (NADAC).
FAERS reports are voluntary and do not establish causation. Drug interactions are derived from FDA labeling and clinical references. This registry does not provide medication decisions.
Last updated: April 30, 2024
PlainMeds is rendered directly from FDA openFDA/FAERS extracts, DailyMed labels, and CMS drug-pricing files, no number is typed in by an editor. FAERS counts, recalls, shortages, and price figures on this page are queried live from those federal extracts. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-05-15. Primary sources: openFDA / FAERS, DailyMed and CMS Part B ASP.
Read our methodology - how this data is sourced, computed, and verified.
Data currency: FDA FAERS adverse-event reports through 2025, CMS NADAC acquisition-cost pricing effective December 2024, compiled from the source snapshot dated . See our methodology for per-source dates and refresh cadence. Spot a figure that looks wrong? Report a data issue.
All federal data sources used on this page
- FDA Orange Book - approved drug products with therapeutic equivalence. accessdata.fda.gov/cder/ob
- FDA DailyMed - NIH-hosted drug labeling for FDA-approved meds. dailymed.nlm.nih.gov
- FDA Adverse Event Reporting System (FAERS) - post-marketing safety surveillance. fda.gov/drugs/faers
- NLM RxNorm - standardized clinical drug nomenclature. nlm.nih.gov/research/umls/rxnorm
- CMS Medicare Part B Drug Average Sales Price Files - federal drug pricing data. cms.gov/medicare/part-b-drugs/asp
- FDA Drug Shortages Database - current and resolved drug shortage tracking. accessdata.fda.gov/drugshortages